The Top 5 Biosimilars Articles for the Week of May 13

The Center for Biosimilars® recaps the top news for the week of May 13, 2019.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 13.

Number 5: The Generic Biosimilar Medicines Association has launched an educational hub for biosimilars.

Number 4: Biosimilar developer Biocon said this week that it will share in the global profits of Hulio, an adalimumab biosimilar.

Number 3: Set against a backdrop of rising concern about the cost of insulin, the FDA held a hearing about biosimilar insulins.

Number 2: Last week, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.

Number 1: AbbVie announced that it has settled its patent litigation with Boehringer Ingelheim over adalimumab.

Finally, last week, our e-newsletter asked how comfortable you think patients and providers should be about switching among biosimilars of the same product.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit